SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending after reporting positive Phase 1 clinical trial data for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile, particularly in treatment-resistant patients. The news has ignited significant community discussion around a potential short squeeze and sustained bullish momentum, with many anticipating future partnerships or a buyout. This early success in a large therapeutic market is generating considerable interest in the stock's long-term potential.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid escalating geopolitical concerns related to potential US-EU trade tariffs and discussions around Greenland, which are generating broad market uncertainty. The community is actively debating the implications, with traders engaged in high-volume options activity as broader indexes experience a sell-off alongside global bond market movements.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market activity following a favorable FDA meeting for its ANKTIVA + BCG bladder cancer application, which did not require new clinical trials, de-risking its path forward. The community is actively discussing a potential short squeeze, fueled by exceptionally high trading volume and strong conviction in the company's transformative cancer therapies. Investors are showing "diamond hands" as they anticipate further positive developments and a re-rating of the stock's value, pushing back against perceived short seller pressure.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to significant market instability sparked by high-profile geopolitical rhetoric and broader financial concerns, including stress in Japan's bond market. The crypto community is intensely debating Bitcoin's status as a reliable hedge asset, noting substantial liquidations even as prominent institutions continue making large acquisitions. This dynamic creates a highly volatile environment and fuels ongoing discussion about its near-term trajectory.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility due to renewed global trade tensions, specifically concerning former President Trump's comments on Greenland and potential tariffs on European allies. The community is sharply divided, with bears anticipating a deeper market correction driven by geopolitical concerns and bond market stability, while bulls are aggressively buying dips, confident in a swift rebound and a potential policy reversal. This dynamic creates significant swings as participants debate the market's underlying strength amidst uncertainty.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its earnings report, with community sentiment sharply divided on whether subscriber growth and ad-tier performance will spark a rally or a significant drop. The recent all-cash offer for Warner Bros. Discovery assets is a key discussion point, seen by some as a strategic play to secure the deal and by others as a potentially costly move impacting future debt. Traders are also noting the stock's oversold conditions, with some positioning for a rebound despite broader market uncertainties.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of Zydus Lifesciences exploring a controlling stake or key asset acquisition, alongside strong preliminary revenue figures and a significant patent extension for IBSRELA and XPHOZAH until 2041. The community is buzzing about the game-changing patent extension, accelerating IBSRELA's path to $1 billion in annual revenue by 2029, and speculating on a potential buyout or bidding war, despite some historical skepticism around sustained gains. Analysts have responded with multiple price target upgrades, highlighting the company's strengthened long-term valuation and potential for sustained growth with two approved drugs.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is a trending topic amidst a prolonged downtrend and consistent selling pressure, defying recent positive reports of strong iPhone sales and market share gains, particularly in China. The community remains sharply divided, with many expressing frustration over its 'oversold' status and speculating on market manipulation, while others view the pullback as a significant buying opportunity ahead of its upcoming earnings report and potential clarifications on its AI strategy, including its partnership with Google Gemini.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is trending due to its persistent decline to multi-year lows, sharply contrasting with broader market gains. This downturn is fueling intense community frustration, with widespread calls for CEO Jeff Green's accountability amidst concerns over competitive pressures from "walled garden" platforms and anticipation building for upcoming earnings as a pivotal event.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following multiple analyst upgrades, renewed investor optimism from CES, and significant news of winning a U.S. SHIELD defense contract for advanced chip manufacturing. The community is actively debating the stock's ability to break through key resistance levels, with many believing the company is undervalued amidst the ongoing AI race and its strategic position in domestic chip production, despite some Wall Street caution ahead of upcoming earnings.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High on Analyst Upgrade

Elanco Animal Health (NYSE:ELAN) Sets New 1-Year High Following Analyst Upgrade...

Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen analysts that are presently covering the company...

Elanco Animal Health (NYSE:ELAN) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded Elanco Animal Health from a "buy" rating to a "strong-buy" rating in a report on Monday...

State of Alaska Department of Revenue Takes Position in Elanco Animal Health Incorporated $ELAN

State of Alaska Department of Revenue bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 3rd quarter, according to the company in its most recent...

New York State Teachers Retirement System Invests $5.50 Million in Elanco Animal Health Incorporated $ELAN

New York State Teachers Retirement System acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 3rd quarter, according to its most recent 13F filing...

ASR Vermogensbeheer N.V. Trims Holdings in Elanco Animal Health Incorporated $ELAN

ASR Vermogensbeheer N.V. cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 18.0% in the third quarter, according to the company in its most recent...

Nisa Investment Advisors LLC Lowers Stock Holdings in Elanco Animal Health Incorporated $ELAN

Nisa Investment Advisors LLC lowered its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 67.4% during the 3rd quarter, according to its most recent filing with the Securities...

Elanco Animal Health (NYSE:ELAN) Sets New 52-Week High - Here's Why

Elanco Animal Health (NYSE:ELAN) Sets New 12-Month High - Here's What Happened...

Stocks Rise as Credit Card Shares Slip on Trump Rate Cap Talk  The Close 1/12/2026

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Former Federal Reserve...

Elanco Animal Health (NYSE:ELAN) Downgraded by Wall Street Zen to "Buy"

Wall Street Zen downgraded Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday...

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.

Current Price	$24.47
Prev Close	$24.53
Open	$23.80
Dividend Yield	0.00%
50-Day Moving Average	$22.43
Beta	1.41
Avg. Volume	5.76M
PE Ratio	336.49

52-Week High	$24.84
52-Week Low	$8.02
Market Capitalization	$12.19B
EPS (Annual)	$0.6797
Price to Book	1.81
Revenue Per Employee	$469,735.45
Enterprise Value/EBITDA	N/A

ELAN
Elanco Animal Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ELAN News

ELANElanco Animal Health Inc